Published in Ocular Surface

EyesUp - Ocular Surface Edition

This is editorially independent content supported by advertising from Sun Pharma
4 min read

Play along with the game EyesUp to learn more about immunomodulators for the treatment of DED.

EyesUp - Ocular Surface Edition
Dry eye disease (DED) affects people worldwide, with prevalence ranging from 5% to 50%.1 In the U.S., about 16.4 million adults have diagnosed DED.2
To address this, immunomodulators are used to help treat the inflammatory cycle that underlies DED.3-5 This may provide a growth opportunity for primary care ODs who screen, diagnose, and start therapies during routine exams.
EyesUp: Ocular Surface Edition, recorded with three optometrist–ophthalmologist pairs, brings fun, fast-paced gameplay together with clinical substance. Teams of two paired up, with one taking the role of host and the other as contestant, to test their knowledge. With only three clues, see how they met the challenge!
Featured in this series are Mark Milner, MD, and Nancy Draskovic-Dosen, OD; Brandon Ayres, MD, and Cecelia Koetting, OD; and Laura Periman, MD, and Chris Kruthoff, OD.

From fungus to treatment

Originally derived from a fungus, cyclosporine helped revolutionize organ transplant medicine through the prevention of organ rejection.3,6
Cyclosporine is a calcineurin inhibitor and has been used in ophthalmic formulations for decades. One aim of this immunosuppressant is to increase tear production in patients living with dry eye.3 Its intended mechanism is to inhibit calcineurin in T-cells, reducing inflammation that can alter the structure or functionally paralyze tear-secreting glands.3,7

Locking in with NCELL

Cyclosporine has poor water solubility, which makes it difficult to deliver through the watery tear film to the ocular surface.3
CEQUA uses NCELL technology to deliver 0.09% cyclosporine.8 Using a hydrophobic core and a hydrophilic outer shell, the formulation encapsulates cyclosporine inside nanomicelles.3 The nanomicelles then penetrate the tear film, delivering the drug into conjunctival and corneal tissue.3,9,10

Artificial in-tear-igence

Artificial tears are a common first stop for dry eye relief. But while artificial tears do lubricate and soothe the irritation that comes with DED, they don't actually treat it.3,5
Patients can continue using previous treatments, like artificial tears, when they start new therapies for dry eye, such as anti-inflammatory therapy like cyclosporine.5

The test of time

Schirmer's test was first developed by German ophthalmologist Otto Schirmer in 1903. Despite being around for more than a century, it’s still a clinical staple.11,12
The non-anesthetized version of this test involves placing a small strip of filter paper under the lower lid. The examiner then measures how many millimeters are wetted in 5 minutes in order to assess basal and reflex tears. The anesthetized test, on the other hand, measures basal tears only.12
For CEQUA’s phase 3 trial, the unanesthetized Schirmer's test was the basis of the primary endpoint. Among 744 patients, 16.6% of eyes treated with CEQUA gained 10 mm or more at day 84 (P < 0.001) vs. 9.2% of eyes in the vehicle group.13

In closing

NCELL, artificial tears, Schirmer’s test, and cyclosporine each fulfill a unique need in the management of dry eye.
Connecting those pieces is what helps clinicians move past temporary relief and achieve real results for their patients. EyesUp: Ocular Surface Edition keeps that clinical foundation sharp, one round at a time.
  1. Stapleton F, Alves M, Bunya VY, et al. TFOS DEWS II epidemiology report. Ocul Surf. 2017;15(3):334-365. doi:10.1016/j.jtos.2017.05.003
  2. Farrand KF, Fridman M, Stillman IÖ, Schaumberg DA. Prevalence of diagnosed dry eye disease in the United States among adults aged 18 years and older. Am J Ophthalmol. 2017;182:90-98. doi:10.1016/j.ajo.2017.06.033
  3. Periman LM, Mah FS, Karpecki PM. A review of the mechanism of action of cyclosporine A: the role of cyclosporine A in dry eye disease and recent formulation developments. Clin Ophthalmol. 2020;14:4187-4200. doi:10.2147/OPTH.S279051
  4. Craig JP, Nichols KK, Akpek EK, et al. TFOS DEWS II definition and classification report. Ocul Surf. 2017;15(3):276-283. doi:10.1016/j.jtos.2017.05.008
  5. Jones L, Downie LE, Korb D, et al. TFOS DEWS II management and therapy report. Ocul Surf. 2017;15(3):575-628. doi:10.1016/j.jtos.2017.05.006
  6. Clavien PA. Jean-François Borel (1933–2025). Transpl Int. 2025;38:15303. doi:10.3389/ti.2025.15303
  7. Stern ME, Pflugfelder SC. Inflammation in dry eye. Ocul Surf. 2004;2(2):124-130. doi:10.1016/S1542-0124(12)70148-9
  8. Cyclosporine mechanism of delivery (MoD): CEQUA® (cyclosporine ophthalmic solution) 0.09% with NCELL® Technology. Cyclosporine Eye Drops. Accessed November 16, 2026. https://www.cequapro.com/ncell-technology.
  9. Weiss SL, Kramer WG. Ocular distribution of cyclosporine following topical administration of OTX-101 in New Zealand white rabbits. J Ocul Pharmacol Ther. 2019;35(7):395-402. doi:10.1089/jop.2018.0106
  10. Sun M, Wang J, Fan W, et al. From design to deployment: the innovative role of nanomicelles in targeted ophthalmic therapeutics. Mater Today Bio. 2025;35:102537. doi:10.1016/j.mtbio.2025.102537
  11. Schirmer O. Studien zur Physiologie und Pathologie der Tränenabsonderung und Tränenabfuhr. Albrecht Von Graefes Arch Ophthalmol. 1903;56(2):197-291. doi:10.1007/BF01946264
  12. Ekici E, Caglar C, Akgümüş EÜ. The repeatability, reproducibility, and correlation of the Schirmer test: a comparison of open versus closed eye. Korean J Ophthalmol. 2022;36(4):306-312. doi:10.3341/kjo.2022.0006
  13. Goldberg DF, Malhotra RP, Schechter BA, Justice A, Weiss SL, Sheppard JD. A phase 3, randomized, double-masked study of OTX-101 ophthalmic solution 0.09% in the treatment of dry eye disease. Ophthalmology. 2019;126(9):1230-1237. doi:10.1016/j.ophtha.2019.03.050
Eyes On Eyecare Editorial Team
About Eyes On Eyecare Editorial Team

Eyes On Eyecare is a digital resource that provides clinical and career education to the young generation of optometrists and ophthalmologists. We work with eyecare professionals to create compelling, educational content available for free to all those in the eyecare industry. To learn more about our team, values, and other projects, visit our About page.

Eyes On Eyecare Editorial Team